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Abstract
Aims Histamine and vascular endothelial growth factor A
(VEGF) are central regulators in vascular pathologies.
Their gene regulation leading to vascular remodeling has
remained obscure. In this study, EC regulation mechanisms
of histamine and VEGF were compared by RNA
sequencing of primary endothelial cells (ECs), functional
in vitro assays and in vivo permeability mice model.
Methods and results By RNA sequencing, similar tran-
scriptional alterations of genes involved in activation of
primary ECs, cell proliferation and adhesion were observed
between histamine and VEGF. Seventy-six commonly
regulated genes were found, representing *53% of all
VEGF-regulated transcripts and *26% of all histamine-
regulated transcripts. Both factors regulated tight junction
formation and expression of pro-angiogenic transcription
factors (TFs) affecting EC survival, migration and tube
formation. Novel claudin-5 upstream regulatory genes
were identified. VEGF was demonstrated to regulate
expression of SNAI2, whereas pro-angiogenic TFs NR4A1,
MYCN and RCAN1 were regulated by both histamine and
VEGF. Claudin-5 was shown to be regulated VEGFR2/
PI3K-Akt dependently by VEGF and PI3K-Akt indepen-
dently by histamine. Interleukin-8 was shown to down-
regulate claudin-5 by histamine. Additionally, SNAI2,
NR4A1 and MYCN were shown to mediate EC survival,
migration and tube formation and to regulate expression of
claudin-5. Further systemic delivery of VEGF and his-
tamine was shown to induce a fast vascular hyperperme-
ability response in intact vasculature of C57/Bl6 mice
followed by regulation of NR4A1 and MYCN.
Conclusions Our study identifies novel claudin-5 upstream
regulatory genes of histamine and VEGF that induce cel-
lular angiogenic processes. Our results increase knowledge
of angiogenic EC phenotype and provide novel treatment
targets for vascular pathologies.
Keywords Vascular endothelial growth factors 
Histamine  Endothelial cell proliferation  Angiogenesis 
Vascular permeability
Introduction
Vascular endothelial growth factor and inflammatory
mediator histamine are well-known edematogenic factors
involved in many vascular diseases. Increased levels of
histamine have been reported in response to trauma,
allergy, burns and infectious diseases [1], whereas
increased VEGF levels are linked to cancer, vascular
anomalies and asthma [2–4]. Both histamine and VEGF
cause vasodilatation, vascular hyperpermeability and local
attraction of inflammatory cells. They are released from
degranulated mast cells, often found near inflammation and
angiogenic sites [5]. Besides their role in hyperperme-
ability, VEGF but also histamine is suggested to induce EC
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proliferation and angiogenesis [6, 7]. Histamine-induced
angiogenesis has been observed in primary ECs [6], rabbit
cornea [8] and after subcutaneous implantation of his-
tamine pellets in mice [6]. Additionally, defective angio-
genesis has been observed in histidine decarboxylase
knockout mouse that catalyzes histamine synthesis [9] and
after treatment with histamine receptor antagonist [7]. In
spite of previous work on early events of histamine and
VEGF signaling, and the use of VEGFs in pro-angiogenic
therapy, gene regulation by which these factors induce
pathological angiogenesis is largely unknown.
Histamine has four receptors (HR1-4) that belong to
G-protein-coupled receptor (GPCR) family, from which
HR1 and HR2 are expressed in ECs. VEGFs instead bind to
VEGF receptors 1–3 (VEGFR), while neuropilins 1–2
(NRP) and heparan sulfate proteoglycans (HSPGs) act as
co-receptors. Several VEGF family members (VEGF-A–F,
placental growth factor) and their isoforms have been
identified [2]. VEGFR2 has been suggested to be the main
receptor responsible for VEGF-induced angiogenesis with
all VEGF family members. In contrast, histamine has been
suggested to induce either expression of (1) VEGF [9] or (2)
NR4A1 (nuclear receptor subfamily 4 group A member 1)
transcription factor [6] that further mediate vascular per-
meability and angiogenesis. So far no genome-wide studies
exist comparing these two pro-angiogenic and edemato-
genic factors that would provide mechanistic insight on
their function in ECs.
The goal of our study was to define the mechanisms
leading to angiogenic phenotype of ECs by histamine and
VEGF and compare whether there are similarities in gene
expression profiles between these factors that could explain
their pro-angiogenic and edematogenic effects. To study
this, we used novel deep-sequencing technology (RNA
sequencing, RNA-seq) that covers information of all
mRNA transcripts of the cell. In comparison with
microarray technology, RNA-seq does not require tran-
script or species-specific probes, is not limited to known
transcripts and is more sensitive to detect genes having low
expression levels. Besides RNA-seq, we used 2-photon
microscopy enabling imaging of 3D organization of the
vasculature and functional assays detecting EC survival,
permeability, migration and tube formation to validate the
data. Our study demonstrates novel common molecular
players involved in angiogenic processes affecting, e.g.,
EC activation, adhesion and proliferation by histamine and
VEGF. We show that *53% of all VEGF-regulated tran-
scripts and*26% of all histamine-regulated transcripts are
commonly regulated, involving genes regulating calcium
signaling, tight junction (TJ) formation and actin re-orga-
nization. Downregulation of the major TJ gene claudin-5
and pro-angiogenic EC phenotype was shown to be
mediated by PI3K signaling and pro-angiogenic
transcription factors SNAI2 (snail family zinc finger 2),
MYCN (N-myc proto-oncogene protein) and NR4A1. No
increase in the expression of VEGFs/VEGFRs by his-
tamine was detected that could explain the commonly
induced genes and functional effects in ECs. Consistently,
after inducing vascular hyperpermeability in C57/Bl6 mice
by histamine or VEGF, changes in expression of claudin-5
upstream regulators NR4A1 and MYCN were observed.
Conclusively, our data demonstrate for the first time that
both histamine and VEGF induce expression of multiple
common genes that regulate EC activation, adhesion and
act as upstream regulators of claudin-5. Understanding the
mechanisms of angiogenic processes and their underlying
gene regulation is crucial for the development of novel
ways to reduce edema in pathological conditions and to
develop pro- and anti-angiogenic therapies.
Methods
Detailed methods section is available in the Data
Supplement.
Experimental animals
All experiments were performed with 8- to 12-week-old
male C57/Bl6 mice (Harlan Laboratories). For vascular
permeability experiments, mice received an intravenous
injection of green fluorescent microspheres (200 nm) fol-
lowed by injection with 0.25 lg/g of human recombinant
VEGFs or 12.5 lg/g (4 h) and 25 lg/g (10 min) of his-
tamine under isoflurane anesthesia. Saline was used as
control. Mice were killed 10 min, 30 min or 4 h after
injections and perfused with PBS (n = 4–5 mice/group).
Tissues were harvested and snap-frozen for qRT-PCR and
western blot (WB). For imaging, tissues were fixed in 4%
PFA-PBS, sliced to 1-mm whole immune mount sections
and immunostained with rat anti-mouse CD31 and goat
anti-rat Alexa 594 antibodies. Animal experiments were
approved by National Experimental Animal Board of
Finland and carried out in accordance with guidelines from
Directive 2010/63/EU of the European Parliament on the
protection of animals used for scientific purposes.
qRT-PCR
Confluent cultures of primary human umbilical vein ECs
(HUVECs, 3–4 donors) or human aortic ECs (HAECs, 3
donors) were starved for 16 h with medium supplemented
with 0.5% FBS. In all experiments, ECs were stimulated
with VEGFs or histamine for 4 or 7 h. Three independent
experiments were performed, containing each of three
replicates. Tissue samples were homogenized with
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Precellys 24 tissue homogenizer. Total RNA was extracted
and reverse transcribed into cDNA using random hexamers
and RevertAid RT. Quantitative measurements of mRNAs
were performed with StepOnePlus Real-Time PCR
System.
RNA-seq
RNA was extracted from histamine- or VEGF-stimulated
HUVECs after 7 h of exposure. Two independent experi-
ments were performed (4 donors, using separate donors in
independent experiments). After enrichment and fragmen-
tation of RNA, poly(A) tailing and cDNA synthesis were
performed [10]. For reverse transcription, an oligo allowing
custom barcoding during final amplification was used.
Libraries were amplified and sequenced on HiSeq 2000
according to the manufacturer’s instructions (GeneCore,
EMBL). RNA-seq was mapped using TopHat (v2.0.7). Each
sequencing experiment was normalized to a total of 107
uniquely mapped tags and visualized by preparing custom
tracks for the UCSC genome browser. Following thresholds
were used: Q value\0.05, RPKM[ 0.5, fold change[1.6.
RNA-seq data were further validated on selected genes by
qRT-PCR by two independent experiments, containing each
of three replicates. The RNA-seq data are available in GEO
under the accession number GSE58663.
Results
Common gene expression profile regulates VEGF-
and histamine-induced changes in EC function
To characterize the transcriptional alterations of genes
inducing angiogenic phenotype of ECs, RNA-seq was per-
formed from HUVECs after 7 h of exposure to histamine or
VEGF. In our omics approach, genes known to regulate EC
and ECM adhesion, proliferation, ion flux and immune
response were compared between the factors. Despite dif-
ferent receptor binding profile of VEGF and histamine to
VEGFR2 and H1R, respectively, 76 genes were shown to be
commonly regulated between VEGF-A165 and histamine
(Fig. 1a, b; Table 1; Suppl. Table 1), representing*53% of
all VEGF-regulated transcripts and*26% of all histamine-
regulated transcripts. Accordingly, 47% of all RNA tran-
scripts (n = 67) were solely regulated by VEGF and*74%
by histamine (n = 215; Table 2). Within the commonly
induced genes, a similar regulation pattern was observed,
having a strong positive correlation (r2 = 0.8; Fig. 1c). To
further identify these gene groups, gene ontology (GO)
analysis was performed. The analysis demonstrated that the
genes were involved particularly in cell differentiation,
development and adhesion (Fig. 1d, f–g; Table 3). Both
factors regulated GPCR signaling involved in calcium
influx/release, cytokine–cytokine interactions as well as
PI3K-Akt pathway involved, e.g., in cell proliferation
(Fig. 1e; Table 4; Suppl. Table 2). Histamine also regulated
genes involved in inflammation, e.g., genes regulating dia-
pedesis, type I interferon pathway, as well as chemokine and
Toll-like receptor signaling pathways. Additionally, acti-
vation of genes involved in complement and coagulation
cascades was detected. To exclude that histamine did not
induce VEGF expression and thereby a similar expression
pattern of commonly regulated genes, qRT-PCR and WB
analyses were performed from histamine-stimulated cells
from 4- to 7-h time points for qRT-PCR and 7 h for WB. No
significant change in VEGF expression was detected either
in qRT-PCR experiments, RNA-seq data or in WB (Suppl.
Table 1; Suppl. Fig. 1A). Additionally, no changes in
expression levels of VEGFRs were detected by RNA-
seq. These data therefore suggest that histamine and VEGF
induce pro-angiogenic phenotype of ECs via similar mech-
anisms despite their different receptor binding profile.
VEGF-mediated vascular hyperpermeability is time
dependent and varies in different vascular beds
Vascular permeability is one of the first indicators of
altered EC adhesion in angiogenesis. In our study,
remodeling of EC adhesion was followed after both short-
(10–30 min) and long-term exposures to histamine or
VEGFR2-binding VEGFs (4, 7 h) in primary human ECs
and in intact vasculature of C57/Bl6 mice, together with
functional in vitro assays and immunofluorescence (IF)
staining of the cell junctional proteins. First, vascular
hyperpermeability response induced by histamine and
VEGFs was compared in the vasculature of C57/Bl6 mice.
Extravasation of fluorescent microspheres from the vessels
was used as an indicator of vascular permeability. After 10
or 30 min of injection of histamine or VEGF and fluores-
cent microspheres (i.v.), mice were killed, perfused and the
vasculature was immunostained by CD31. Due to its well-
known and relative simple organization of 3D vasculature,
trachea was used as a target tissue to detect the vascular
leakage. Additionally, biodistribution, i.e., vascular leak-
age of the fluorescent particles, was detected from liver,
spleen, kidney, heart and the lungs. After 10 min of
exposure, vascular leakage of 200-nm fluorescent micro-
spheres was visible by laser scanning microscopy in *20-
lm-sized vessels of trachea with HR1/2-binding histamine,
VEGFR1/2-binding VEGF-A165 and VEGFR2-binding
VEGF-F, indicating a fast hyperpermeability response of
the vessels (Fig. 2a) due to gap formations between ECs.
No vascular leakage was detected after injection of
VEGFR2/3-binding VEGF-DDNDC, having lower affinity
Angiogenesis (2017) 20:109–124 111
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binding to VEGFR2 [11], or saline-injected control mice.
Quantification of microspheres from CD31-labeled vessels
showed a 49-fold increase of vascular permeability in
histamine and a eightfold increase in VEGF-F-treated mice
(Fig. 2b, c), whereas no statistically significant effect was
detected with VEGF-A165 after 10 min of exposure (1.6-fold,
Q[ 0.05). Instead, 30 min after injection a 17-fold
increase in vascular permeability was detected with VEGF-
A165 and a 12-fold with VEGF-F (Fig. 2h), demonstrating
that vascular hyperpermeability induced by VEGFs
increased over time. No differences between treatments
were detected in liver (10 or 30 min; Fig. 2d), whereas
Fig. 1 Histamine and VEGF regulate pro-angiogenic gene expres-
sion similarly in ECs. a RNA-seq was performed from HUVECs
treated with VEGF-A165 (100 ng/ml) or histamine (20 lM) for 7 h.
Venn diagram showing all significantly regulated genes in treated
ECs, revealing 76 commonly regulated genes. b Heat map showing
all genes in non-treated ECs (Notx) and in VEGF- or histamine-
treated ECs. Normalized gene expression values are shown (red,
upregulated; green, downregulated genes). c–d Scatter plot (c) and
gene ontology analysis (d) of commonly regulated genes. e KEGG
pathway analysis of commonly regulated genes (gray), histamine
(black) and VEGF (white) regulated genes. f–g Gene ontology
analyses of histamine- (f) and VEGF-regulated genes (g). In all data,
two independent experiments from separate donors were performed
(n = 4 donors)
Table 1 Top 10 commonly
upregulated genes after VEGF
or histamine stimulation in
HUVECs at 7-h time point
Gene symbol LogFC (VEGF) FDR (VEGF) LogFC (histamine) FDR (histamine)
Commonly regulated genes
STC1 5.03 2.11E-129 2.11 2.74E-09
PMCH 2.69 3.33E-05 4.41 8.77E-31
NR4A1a 2.34 5.15E-18 1.66 1.20E-07
A2M 1.98 4.15E-13 1.11 3.04E-03
CCL20 1.81 3.99E-02 3.77 2.18E-16
DNALI1 1.70 1.81E-12 1.67 1.93E-13
LBH 1.40 4.04E-12 2.58 1.25E-55
RCAN1a 1.23 9.17E-26 2.13 5.14E-77
KITLG 1.21 2.11E-18 1.80 3.80E-27
HDAC9 1.14 1.16E-03 1.59 3.00E-08
STC1 stanniocalcin 1, PMCH pro-melanin-concentrating hormone, NR4A1 nuclear receptor subfamily 4,
group A, member 1, A2M alpha-2-macroglobulin, CCL20 chemokine (C–C motif) ligand 20, DNALI1
dynein, axonemal, light intermediate chain 1, LBH limb bud and heart development, RCAN1 regulator of
calcineurin 1, HDAC9 histone deacetylase 9
a Commonly upregulated transcription factors
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VEGF-F caused a fivefold less vascular leakage in spleen
at 10-min time point compared to other VEGFs or his-
tamine (Fig. 2e). Additionally, no leakage of microspheres
was detected in kidneys or heart. To further distinguish the
role of VEGF co-receptors NRP1/2 and HSPGs in VEGF-
induced vascular hyperpermeability, experiments were
performed with VEGF isoform A121 which has reduced
binding affinity to NRP receptors and HSPGs compared to
VEGF-A165 or VEGF-F and increased solubility [11]. At
30-min time point, VEGF-A121 did not induce statistically
significant vascular permeability in trachea (Fig. 2f, h),
whereas in the lungs and spleen, a twofold increase in
vascular leakage of the fluorescent particles was detected
(Fig. 2i, j). Therefore, VEGF binding to NRP receptors or
Table 2 Top 10 VEGF- or
histamine-specific genes
upregulated in HUVECs at 7-h
time point
Gene symbol Gene name FDR
VEGF specific
MEF2Ca Myocyte enhancer factor 2C 3.66E-29
DNAJB9 DnaJ (Hsp40) homolog, subfamily B, member 9 1.34E-17
ST8SIA4 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4 7.69E-10
SULT1C4 Sulfotransferase family, cytosolic, 1C, member 4 9.99E-10
ARHGAP20 Rho GTPase-activating protein 20 1.96E-06
PDGFD Platelet-derived growth factor D 2.46E-06
PRDM1 PR domain containing 1, with ZNF domain 2.41E-05
EGR3a Early growth response 3 5.08E-05
MYCNa v-Myc myelocytomatosis viral-related oncogene 9.45E-04
SNAI2a Snail homolog 2 4.72E-02
Histamine specific
SERPINB2 Serpin peptidase inhibitor 1.36E-125
FST Follistatin 1.70E-102
AKAP12 A kinase (PRKA) anchor protein 12 5.60E-81
RELN Reelin 8.05E-69
PLAU Plasminogen activator, urokinase 1.25E-55
PLAT Plasminogen activator, tissue 1.68E-50
SEMA3A Semaphorin 3A 1.01E-46
MALL Mal, T cell differentiation protein like 2.62E-39
PEG10 Paternally expressed 10 1.80E-32
MYADM Myeloid-associated differentiation marker 1.15E-25
a Upregulated transcription factors and transcription enhancer factors
Table 3 GO analysis of commonly regulated genes in HUVEC cells after 7 h of VEGF and histamine exposure
GO Term Genes
GO:0045595
GO:0050793
Regulation of cell
differentiation
and developmental process
PTHLH, DLL1, FITM2, AQP1, MAFB, KITLG, RCAN1, SMOC1, HGF, GDPD5, SEMA6A,
ABCA1, HDAC9, GDF7
GO:0048731
GO:0009888
GO:0048513
Organ, system and tissue
development
CLDN5, PTHLH, NR4A1, AQP1, MYO7A, MAFB, KALRN, TNFSF10, SMOC1, RCAN1,
GDPD5, SEMA6A, DOK5, HDAC9, CYP1A1, DLL1, KITLG, HGF, SLC12A2, STC1,
NLGN4Y, GDF7
GO:0007154 Cell communication PTHLH, CCL20, NR4A1, PMCH, A2M, KALRN, TNFSF10,
DNAJB11, SMOC1, RCAN1, RASD1, SEMA6A, DOK5, HDAC9, DLL1, BCL2A1, KITLG,
ARHGAP28, OPRL1, HGF, ANXA9, SLC12A2, ABCA1, STC1, GDF7
GO:0071320 Cellular response to cAMP STC1, AQP1
GO:0002673 Regulation of acute
inflammatory response
ALOX5AP, A2M
GO:0007186 G-protein-coupled receptor
signaling pathway
RASD1, OPRL1, PTHLH, SLC12A2, PMCH, ABCA1
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HSPGs seems to further affect the permeability profile
induced by VEGFs. In accordance with in vivo results,
permeability assay in HUVECs showed that VEGF-A165
significantly induced EC permeability of a fluorescent
marker after 15 min of exposure, whereas VEGF-A121 or
VEGF-DDNDC had no effect (Suppl. Fig. 1D). Redistribu-
tion of VE-cadherin, a major adherens junction (AJ) pro-
tein and changes in F-actin organization were also seen
30 min after exposure to VEGF-A121, VEGF-A165, VEGF-
F and histamine, whereas VEGF-DDNDC did not induce any
major changes (Suppl. Fig. 1B). Taken together, these data
confirmed that both histamine and all high affinity binding
VEGFR2 ligands regulate EC–EC adhesion and vascular
permeability by modulating VE-cadherin and F-actin
organization. Previously, no corresponding studies have
been performed that would have compared these VEGF
family members in intact vasculature of mice after sys-
temic delivery. Additionally, co-receptor binding to NRPs/
HSPGs was shown to be an important factor influencing
VEGF-mediated vascular permeability response. Due to
the heterogeneity of the endothelium in different organs,
vascular permeability response was shown to be dependent
on the detected vascular bed, emphasizing the importance
to study vascular permeability of all edematogenic factors
in various target tissues.
Expression of a major tight junction protein
claudin-5 is downregulated by histamine
and VEGFR2-binding VEGFs after long-term
stimulation
Previously, several studies have shown that short-term
exposure to histamine or VEGF-A165 induces phosphory-
lation cascades that affect formation of AJs [12, 13].
However, changes in EC gene expression leading to
pathological angiogenesis are not well known, although
both histamine and VEGF have been connected to various
pathological states. To gain more detailed understanding of
the long-term regulation of EC–EC adhesion by histamine
and VEGFs leading pro-angiogenic EC phenotype, we
studied this further in primary venous and aortic ECs at 4-
and 7-h time points after stimulation. By RNA-seq
(HUVEC, 7 h) both histamine and VEGF were shown to
regulate expression of genes involved in AJ and TJ cell–cell
adhesion modulation as well as organization of actin fila-
ments that mediate gap formation between ECs (Fig. 3a;
Suppl. Fig. 1C). By IF staining, downregulation of the
major TJ protein claudin-5 (CLDN5) was evident, whereas
no detectable changes in the expression of the major AJ
protein VE-cadherin (CDH5) was seen in HUVECs at 7-h
time point (Fig. 3b). To further confirm that VE-cadherin
Table 4 Gene regulation of
major signaling pathways by
VEGF and histamine in
HUVEC cells after 7 h of
exposure
ID term (pathway) Term Genes
hsa04060 Cytokine–cytokine receptor interaction
VEGF-A KITLG, TNFSF10, HGF, CCL20
CCL7, BMP2, TNFSF13, CXCL11, CCL20a,
Histamine IL8, TNFSF10a, KITLGa, HGFa, GDF5
hsa04151 PI3K-Akt signaling pathway
VEGF-A
Histamine
PDGFD, KITLG, HGF, BCL2L11, NR4A1
KITLGa, HGFa, RELN, ITGB8, NR4A1a
hsa04610 Complement and coagulation cascades
Histamine PLAU, PLAT, SERPIND1, A2Ma
hsa04068 FoxO signaling pathway
VEGF-A TNFSF10a, FBXO32a, BCL2L11
hsa04015, hsa04014 Rap1 and Ras signaling pathways
VEGF-A
Histamine
PDGFD, KITLG, HGF
KITLGa, HGFa, MAP2K6
hsa04350 TGF-beta signaling pathway
Histamine BMP2, FST, GDF5, GDF7a
hsa04064 NF-kappaB signaling pathway
Histamine BIRC3, PLAU, BCL2A1a, IL8
hsa04668 TNF signaling pathway
Histamine BIRC3, CCL20a, RPS6KA5, MAP2K6
hsa04390 Hippo signaling pathway
Histamine BMP2, GDF5, TEAD2, GDF7a
a Common genes with VEGF and histamine
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expression levels were not changed in stimulated ECs, qRT-
PCR was performed, showing that only a slight increase
was detected in VE-cadherin mRNA levels after 7 h of
exposure by VEGF-A165, VEGF-F and histamine (Suppl.
Fig. 1E). Consistently with the results at 30-min time point,
re-organization of VE-cadherin on the cell surface of his-
tamine- or VEGF-stimulated ECs was visible at 7-h time
point (Fig. 3b). Next, we validated CLDN5 expression by
qRT-PCR experiments. The results further confirmed the
significant downregulation of CLDN5 in both venous
(HUVEC; 4, 7 h) and aortic (HAEC; 7 h) primary ECs after
exposure by VEGF-A121, VEGF-A165, VEGF-F and his-
tamine, whereas VEGF-DDNDC had no effect (Fig. 3c;
Suppl. Fig. 1F). Being in line with in vitro data, a trend in
CLDN5 downregulation was detected in lung tissue of C57/
Bl6 mice after 4 h of exposure (i.v.) to VEGF-A165, VEGF-
F or histamine, albeit the effect was not statistically sig-
nificant (Suppl. Fig. 1H). These data implicated that high
affinity binding of VEGF to VEGFR2 regulates CLDN5
expression and thereby EC–EC adhesion.
To further address the question, whether histamine-
and VEGF-induced CLDN5 downregulation was specific
Fig. 2 Tissue-specific and time-dependent vascular hyperpermeabil-
ity in intact vasculature of mice after short-term induction by
histamine and VEGFs. a Tracheal whole mounts labeled with
endothelium marker CD31 (red). Intravenous administration of
histamine (25 lg/g) or VEGFs (0.25 lg/g) together with 200-nm
fluorescent microspheres (green) in C57/Bl6 mice at 10 min after
exposure. NaCl was used as a negative control together with
fluorescent microspheres (untreated). Scale bar, 100 lm. b–e Quan-
tification of the vascular leakage from trachea (b, c), liver (d) and
spleen (e) at 10 min after exposure. f, g Close-up and plot profile
views of the 20-lm-sized leaky vessels are presented after 30 min of
exposure to VEGFs, showing fluorescent microspheres (green line)
outside of the vessels (red line, f). White bars represent the site from
which the corresponding intensity plot profile area is derived (g). h–
j Quantification of vascular leakage from trachea (h), lung (i) and
spleen (j) at 30 min after VEGF exposure. In all data, mean ± SEM
presented (n = 4–5 mice/group). Q values \0.05*; \0.01**;
\0.001***
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Fig. 3 Regulation of cell–cell adhesion by histamine and VEGFs in
ECs. a Heat map showing genes in cell–cell adhesion after VEGF and
histamine stimulation for 7 h in HUVEC cells by RNA-seq. Normalized
gene expression values are shown (red, upregulated; green, downreg-
ulated genes). In all data, two independent experiments from separate
donors were performed (n = 4 donors). b VE-cadherin (CDH5 Ab,
upper panel, green) and claudin-5 (CLDN5 Ab, lower panel, green)
immunofluorescent staining of HUVECs after VEGF treatment for 7 h
showed claudin-5 downregulation induced by both VEGF and
histamine. No changes were detected in VE-cadherin expression.
DAPI (blue) was used for staining nuclei. c mRNA expression levels of
CLDN5 after 4- and 7-h stimulation with histamine or VEGFs in
HUVECs detected by qRT-PCR. d CLDN5 mRNA expression levels in
VEGFR2 (siVEGFR2) or control (siCTRL) siRNA-silenced HUVECs
after 7-h stimulation with histamine or VEGF-A detected by qRT-PCR.
e Genes involved in the regulation of transcriptional activity by VEGF
and histamine. Log fold changes are shown. In all data, two
independent experiments from separate donors were performed
(n = 4 donors). f CLDN5 mRNA expression levels in zinc finger
protein SNAI2 (siSNAI2) or control (siCTRL) siRNA-silenced
HUVECs after 7-h stimulation with histamine or VEGF-A detected
by qRT-PCR. g Migration assay in HUVECs after 48-h siRNA
treatment with siSNAI2 and siCTRL. Cell staining was performed in
order to visualize EC migration according to manufacturer’s instruc-
tions (3 independent experiments; n = 3 wells/siRNA) and visualized
with brightfield microscopy. Magnification 209. H–j In vitro tube
formation assay in HUVECs after 48-h siRNA treatment with siSNAI2
and siCTRL and 7-h stimulation with histamine or VEGF (h). Field
area (i) and number of tubules (j) are shown. Quantitation of tubules
was performed by Angiosys program. In all data, mean ± SEM
presented. Q values \0.05*; \0.01**; \0.001***. All experiments
were performed with VEGF concentration of 100 ng/ml and with
20 lM histamine. In all experiments, 3 independent experiments were
performed (3 replicates/experiment, HUVEC\ p5)
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to their vascular permeability-inducing receptors H1R and
VEGFR2, siRNA experiments against VEGFR2 and H1R
inhibitor experiments were performed. In siVEGFR2-
treated ECs, histamine but not VEGF was able to down-
regulate CLDN5 expression (Fig. 3d). Similarly, his-
tamine receptor inhibitor was able to block histamine-
mediated CLDN5 downregulation but had no effect on
VEGF (Suppl Fig. 1g). Therefore, these data demonstrate
that CLDN5 is regulated independently by both histamine
and VEGF. Interestingly, RNA-seq data showed that in
addition to downregulation of CLDN5 by both VEGF and
histamine, both factors regulated several other junctional
molecules independently. VEGF was shown to downreg-
ulate cell–cell adhesion genes such as immunoglobulin
superfamily cell adhesion receptors (AMIGO3, CADM4)
and junction adhesion molecule 2 (JAM2). Histamine
instead regulated other genes associated with TJs, e.g.,
claudin superfamily members (CLDN1, CLDN14), Cox-
sackie virus and adenovirus receptor (CXADR), cingulin-
like 1 (CGNL1), membrane-associated guanylate kinase
CNKSR3 and membrane protein MPP7 (Fig. 3a). These
data suggest that regulation of EC adhesion is a complex
process, in which multiple genes play a role simultane-
ously. CLDN5 was shown to be the main adhesion gene
regulated by both histamine and VEGF. We also
demonstrated that high affinity binding of VEGFs to
VEGFR2 and histamine binding to H1R regulate CLDN5
expression. To conclude, although it has been shown that
internalization of VE-cadherin due to well-known phos-
phorylation cascades is an important factor in induction of
EC permeability after short-term stimulation by histamine
and VEGF, CLDN5 is also regulated at the expression
level in both venous and aortic ECs. Interestingly, prior to
our study, CLDN5 expression has been demonstrated to
affect EC cell motility and matrix adhesion [14, 15].
VEGF regulates gene expression of claudin-5
via a transcription factor SNAI2
Transcription factors (TFs) are crucial in regulating
angiogenic processes. Therefore, we studied further the
role of pro-angiogenic TFs regulating CLDN5 expression
in histamine- and VEGF-stimulated ECs. Previously sev-
eral studies have shown regulation of CLDN5 by tran-
scription factors such as FoxO1, ERG and RUNX1
[16–18]. However, common histamine- and VEGF-induced
CLDN5 upstream regulators have not been previously
presented and the separate studies have usually focused
only on one TF [17, 18]. In our omics approach, we
detected by RNA-seq multiple TFs regulated by both his-
tamine and VEGF, such as NR4A1, RCAN1 and MAFB
(7 h, HUVEC). Additionally, 13 other TFs were specifi-
cally regulated by histamine and 8 TFs by VEGF such as
SNAI2 (Fig. 3e). Since SNAI2 has been previously sug-
gested to act as a transcriptional regulator of claudin-1 in
keratinocytes [19] and to enhance cancer cell migration,
this TF was studied first. In VEGF-treated ECs, SNAI2
expression was shown to be upregulated by 2.8-fold
(Q\ 0.01), while transcript levels were unchanged in
histamine-treated HUVECs. To distinguish the role of
SNAI2 and VEGFR2 signaling in potentially regulating
CLDN5 expression and angiogenic processes in ECs, we
next performed siRNA experiments against SNAI2 and
detected the mRNA levels of CLDN5 by qRT-PCR. In
addition, functional effects of SNAI2 to EC survival, tube
formation, proliferation and migration were followed. First,
silencing of SNAI2 (Suppl. Fig. 2A) was shown to inhibit
VEGF-mediated CLDN5 downregulation but not his-
tamine-induced effects in HUVECs (Fig. 3f). In functional
assays, EC tube formation (HUVEC, 48 h; Fig. 3h–j;
Suppl. Fig. 1I), measured by field covered by the tubules as
well as by number of tubules and junctions, showed sig-
nificant decrease of tube formation after treatment with
siSNAI2, indicating a role for SNAI2 in regulating EC
sprouting. Consistently, siSNAI2 treatment was shown to
regulate EC migration (48 h, Fig. 3g; Suppl. 2K) and EC
survival measured by MTS assay (72 h, Fig. 4m). How-
ever, no significant effect was found on EC proliferation in
comparison with control siRNAs (72 h, CyQuant assay;
data not shown). IF staining of F-actin in siSNAI2-treated
HUVECs further showed F-actin reorganization in con-
fluent ECs and after EC tube formation (Suppl. Fig. 1J).
Previously, F-actin has been shown to be important in
migration and tube formation of ECs and to be associated
with TJs. Conclusively, SNAI2 was shown to be an
important mediator of VEGF signaling via regulating
CLDN5 and F-actin organization and affecting EC tube
formation and migration. Our data further demonstrate that
SNAI2 is specific for VEGF and is not regulated by
histamine.
TJ formation is regulated via PI3K signaling
by VEGF but is independent of HGF expression
To further define histamine- and VEGF-regulating angio-
genic factors, we next assessed the role of cytokines and
other growth factors that could influence EC proliferation
and adhesion. To study this, we first detected all genes in
our RNA-seq data that were involved in regulation of
extracellular matrix (ECM) organization, as well as
cytokines and growth factors. Altogether, 18 transcripts
regulating ECM remodeling were detected by RNA-seq in
histamine-treated ECs (7 h, HUVEC, Fig. 4a). Histamine
modulated, e.g., matrix metalloproteinases (MMP10,
MMP19), crucial in angiogenesis-associated cell migration,
as well as a serine protease reelin (RELN), whereas VEGF
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regulated ADAM metallopeptidase (ADAMTS10) and
MMP28. Whereas only minority of ECM genes were reg-
ulated similarly between histamine and VEGF, instead 14
commonly regulated genes were shown to be commonly
involved in EC proliferation, such as hepatocyte growth
factor (HGF; Fig. 4b; Table 3). Since HGF has previously
been shown to regulate TJ formation and angiogenesis via
PI3K-Akt pathway [20, 21] and could therefore act as a
common nominator to histamine- and VEGF-induced
CLDN5 downregulation, this was studied further. First,
WB analysis of HGF-stimulated HUVECs was performed
to confirm that HGF does not induce VEGF expression that
could explain the similar expression profiles of histamine
and VEGF. No increase in the expression level of VEGF
protein was observed (7 h, HUVEC; Suppl. Fig. 1A). Next,
we performed siRNA experiment against HGF receptor
MET and detected CLDN5 expression levels after his-
tamine or VEGF stimulation. No inhibition of CLDN5
downregulation by VEGF or histamine was observed
(Fig. 4c), indicating that HGF does not act as a regulator of
CLDN5. Consistent with previous data [20, 21], upregu-
lation of HGF was inhibited in PI3K inhibitor-treated ECs
(7 h; Fig. 4d). Conclusively, although PI3K-Akt pathway
was shown to be required for VEGF- and histamine-in-
duced HGF mRNA upregulation, HGF is not the common
mediator required for regulating CLDN5 expression and
subsequent TJ formation.
Our results with PI3K inhibitor (Fig. 4e) showed that
PI3K-signaling was required particularly for VEGF-in-
duced CLDN5 downregulation, whereas no effect was
observed with histamine. This implied that another
mechanism for histamine-induced effects existed, such as
signaling via interleukin-8 (IL-8; Fig. 4b). In previous
studies, IL-8 has been shown to downregulate CLDN5
expression in ECs and to induce vascular permeability
[22]. In our study, IL-8 was upregulated by histamine but
not by VEGF detected by qRT-PCR (HUVEC, 7 h;
Fig. 4f). To observe whether PI3K-signaling was involved
in IL-8 expression, we performed qRT-PCR experiments
with PI3K inhibitor-treated ECs. The data showed that
inhibition of PI3K-signaling did not affect histamine-in-
duced IL-8 upregulation (HUVEC, 7 h, Fig. 4f) or
CLDN5 downregulation (Fig. 4d). These data indicated
that IL8 could act as an indirect mediator of CLDN5
expression in histamine-stimulated ECs. Consistently, in
siRNA experiments against IL-8, VEGF but not histamine
was able to downregulate CLDN5 expression (Fig. 4g).
To conclude, we show evidence that histamine and VEGF
regulate TJ formation via complex and partially different
cellular mechanisms, requiring IL8- and PI3K-Akt-de-
pendent and independent pathways. Additionally, both
factors induced upregulation of HGF; however, this
growth factor did not have an effect on CLDN5
expression.
VEGF and histamine both regulate expression
of pro-angiogenic transcription factors NR4A1
and MYCN that mediate CLDN5 expression
and angiogenic processes in ECs
To obtain understanding whether common CLDN5
upstream regulators existed by histamine and VEGF, we
next studied various TFs found from RNA-seq data by
siRNA experiments and functional assays in ECs. Of all the
TFs, RCAN1 (regulator of calcineurin 1), NR4A1 (nuclear
receptor subfamily 4 group A member 1) and MYCN (N-
myc proto-oncogene protein) were the most highly upreg-
ulated TFs by histamine and/or VEGF and were thus
chosen for further studies (Fig. 3e; Tables 1, 2). Besides
7-h time point used in RNA-seq, all of the studied TFs were
cFig. 4 Regulation of EC proliferation by histamine and VEGFs.
a Heat map showing genes involved in cell–ECM adhesion regulated
by VEGF and histamine (7 h) in HUVECs by RNA-seq. Normalized
gene expression values are shown (red, upregulated; green, down-
regulated). b Genes involved in the regulation of growth factors and
cytokines by VEGF and histamine. Log fold changes are shown. In all
data, two independent experiments from separate donors were
performed (n = 4 donors). c HGF signaling does not regulate
CLDN5. CLDN5 mRNA expression levels in siMET or siCTRL
siRNA-treated HUVECs after stimulation with histamine or VEGF-A
(7 h). d PI3K-Akt pathway is required for HGF upregulation. HGF
expression in untreated and PI3K inhibitor-treated HUVECs after
histamine and VEGF stimulation for 7 h detected by qRT-PCR.
e PI3K-Akt pathway is required for CLDN5 downregulation by
VEGF. CLDN5 expression in untreated and PI3K inhibitor-treated
HUVECs after histamine and VEGF stimulation detected by qRT-
PCR. f IL-8 is upregulated by histamine but not by VEGF. Inhibition
of PI3K-signaling was not able to inhibit histamine-induced IL-8
upregulation. IL8 expression in untreated and PI3K inhibitor-treated
HUVECs after 7-h VEGF and histamine stimulation is shown
detected by qRT-PCR. g CLDN5 mRNA expression levels in siIL-
8-treated HUVECs after histamine and VEGF stimulation for 7 h
detected by qRT-PCR. h Upregulation of transcription factors NR4A1
and MYCN in HUVECs after histamine and VEGF stimulation (7 h).
i Upregulation of NR4A1 mRNA expression and downregulation of
MYCN in lung tissue by histamine and VEGFs after 4 h of systemic
delivery detected by qRT-PCR (n = 3–4 mice/group). j NR4A1
regulates TJ formation. CLDN5 expression in siNR4A1, siMYCN or
siCTRL siRNA-treated HUVECs after 7-h stimulation with histamine
or VEGF detected by qRT-PCR. k MYCN protein expression is
upregulated by VEGFs, but not by histamine in HUVECs after 7 h of
treatment detected by WB. l In vitro tube formation assay in HUVECs
after 48-h siRNA treatment with siMYCN and 7-h stimulation with
VEGF. Representative images are shown. m EC survival was
decreased by siRNAs against MYCN, NR4A1 and SNAI2 detected
by MTS assay (48 h). In all data, mean ± SEM presented. Q values
\0.05*;\0.01**;\0.001***. All experiments were performed with
VEGF concentration of 100 ng/ml and with 20 lM histamine. In all
cell experiments, 3 independent experiments were performed (3
replicates/experiment, HUVEC\ p5)
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shown to be upregulated at 4 h by qRT-PCR (Fig. 4i;
Suppl. Fig. 2C).
First RCAN1 was studied that has been previously
linked with overload of calcium in ECs and vascular per-
meability [23]. In line with previous studies showing his-
tamine- and VEGF-induced calcium influx [24], we
observed multiple genes known to be involved in calcium
uptake that were regulated commonly by both histamine
and VEGF (Suppl. Fig. 2B). qRT-PCR data confirmed that
RCAN1 was upregulated after stimulation with various
VEGFR2-binding VEGFs and by histamine at both 4- and
7-h time points (Suppl. Fig. 2C). To further distinguish the
role of VEGFR2 in RCAN1 expression, siRNA experi-
ments were performed against VEGFR2. The data showed
that histamine but not VEGF upregulated RCAN1
expression (Suppl. Fig. 2D), thus indicating that both fac-
tors mediate RCAN1 expression independently regardless
of their distinct receptor binding profiles. Besides RCAN1,
both histamine and VEGF commonly regulated several
other calcium-activated genes, e.g., plasma membrane
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calcium-transporting ATPase 1 (ATP2B1; Suppl. Fig. 2b,
E), sodium/chloride transporter SLC12A2 and stanniocal-
cin-1 (STC1; Suppl. Fig. 2B, F). Interestingly, no signifi-
cant changes were found in the expression levels of
RCAN1, STC1, ATP2B1 or SLC12A2 by VEGF-A121
(Suppl. Fig. 2C, E, F), whereas VEGF-F, a selective ligand
of VEGFR2, induced a similar expression pattern of cal-
cium-induced genes as VEGF-A165. These data indicated
that expression of calcium-activated genes was linked to
HSPG/NRP co-receptor binding of VEGFs. Finally, to
detect the potential role of RCAN1 in angiogenic pro-
cesses, a migration assay was performed in siRNA-treated
ECs against RCAN1. The data showed no effect on EC
migration in comparison with control siRNA (48 h, Suppl.
Fig. 2J). Therefore, we focused our study to other his-
tamine- and VEGF-regulated TFs MYCN and NR4A1 that
could potentially regulate EC adhesion and angiogenic
processes.
High upregulation of NR4A1 expression, an orphan
nuclear superfamily member, has been previously shown
to be involved in angiogenesis and inflammation [6, 25].
Consistently, in our study NR4A1 was upregulated in
HUVECs at 4-h and 7-h time points by both histamine and
VEGF (Fig. 4i; Suppl. Fig. 2G). Upregulation of NR4A1
was also detected in the lung tissue of C57/Bl6 mice after
systemic delivery (i.v.) of both histamine, VEGF-A165
and VEGF-F after 4 h of exposure (Fig. 4i). In compar-
ison, MYCN gene expression, linked with regulation of
cell proliferation, e.g., in neuroblastoma [26], was
upregulated in ECs by all studied VEGFs at 4- and 7-h
time points detected by RNA-seq, qRT-PCR and WB but
only at 4-h time point with histamine (Fig. 4h, k; Suppl.
Fig. 2G). A different role of MYCN in ECs compared to
lung tissue was seen after systemic delivery of VEGF-
A165, VEGF-F or histamine in C57/Bl6 mice, as MYCN
was shown to be downregulated (i.v., 4 h; Fig. 4h). The
importance of NR4A1 and MYCN in EC function was
further analyzed in a cell survival, proliferation, migration
and tube formation assays in HUVECs. The data
demonstrated a significant decrease in EC survival after
siRNA treatment against NR4A1 or MYCN (72 h, MTS
assay; Fig. 4m; Suppl. Fig. 2A); however, no significant
increase in cell proliferation (72 h, CyQuant assay, data
not shown) or significant effect on EC tube formation was
observed with either NR4A1 or MYCN (48 h, Fig. 4l;
Suppl. Fig. 2H). In migration assay instead, siNR4A1
increased EC migration (48 h, Suppl. Fig. 2J, K), showing
that these factors are important regulators of EC adhesion.
Next, to address the question whether MYCN or NR4A1
regulates CLDN5 expression and thereby affects EC
adhesion/migration, qRT-PCR experiments were per-
formed in siRNA-treated ECs. Treatment of ECs with
siRNA against MYCN was shown to inhibit only
VEGF-induced CLDN5 downregulation, whereas no
effect was observed with histamine (HUVEC, 7 h;
Fig. 4i). Instead either histamine or VEGF was not able to
downregulate expression of CLDN5 in siNR4A1-treated
ECs (HUVEC, Fig. 4j). Consistently, in ECs treated with
siCLDN5 histamine and VEGF were still able to upreg-
ulate NR4A1 (data not shown). Thus, these data demon-
strated that NR4A1 acts as an upstream regulator of
CLDN5. Finally, to further study the role of VEGFR2 in
inducing NR4A1 upregulation, experiment with siRNA
against VEGFR2 was performed. The data showed that
upregulation of NR4A1 was independent on VEGFR2
expression (Suppl. Fig. 2I). Conclusively, these data
indicate that an indirect mechanism, independent of
VEGFR2 signaling, induces upregulation of NR4A1 after
stimulation by histamine and VEGF and downregulates
CLDN5 expression. Interestingly, NR4A1 has been pre-
viously shown to be upregulated by inflammation medi-
ators TNF-alpha and interleukin-1b [27].
Altogether, these data demonstrate that both edemato-
genic factors VEGF and histamine regulate multiple genes
Fig. 5 Claudin-5 downregulation by histamine and VEGF in ECs.
a Histamine and VEGF-A commonly downregulated CLDN5 via
NR4A1. VEGF-A induced VEGFR2-mediated CLDN5 downregula-
tion via PI3K pathway (blue lines), whereas histamine-induced
CLDN5 downregulation via IL-8 (red lines). We hypothesize that
snake venom-derived VEGF-F induces NR4A1 expression due to
inflammation signaling. b CLDN5 as a molecular target of VEGF or
histamine. Molecules found to be involved in this study are shown
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involved in EC adhesion, calcium signaling and EC
migration that induce the development of pro-angiogenic
EC phenotype (Fig. 5). Regulation of CLDN5 expression
by VEGF and histamine involves PI3K signaling and
previously unknown CLDN5 upstream regulators SNAI2,
NR4A1 and MYCN. Prior to this study, these factors and
RCAN1 have not been linked to histamine. Additionally,
histamine was shown to regulate angiogenic cellular pro-
cesses independently of VEGFR2.
Discussion
Physiological effects of VEGFs and histamine on the
vasculature are well established, but postreceptor signaling
pathways and gene regulation affecting angiogenesis are
not fully understood. Using RNA-seq and functional
assays, we compared gene regulation by VEGF and his-
tamine in primary ECs and in the vasculature of C57/Bl6
mice after systemic delivery. Altogether, 76 commonly
regulated genes were found between histamine- and
VEGF-stimulated ECs by RNA-seq, representing*53% of
all VEGF-regulated transcripts and *26% of all his-
tamine-regulated transcripts. Several of the genes encoded
proteins important for cell junction stability, cytoskeleton
organization and cell–ECM adhesion thereby affecting EC
integrity and proliferation. Particularly, VEGF induced
changes in the immunoglobulin superfamily cell adhesion
receptors and genes involved in the stabilizing/regulating
TJs and AJs, whereas histamine regulated mainly tran-
scripts linked to TJ function. Both histamine and VEGF
reduced expression of the major TJ protein claudin-5 that
has previously been connected to pathological angiogene-
sis, increased macromolecule influx [28] and blood–brain
barrier breakdown [29]. Although changes in VE-cadherin
and F-actin organization were found after both short- (4 h)
and long-term stimulation (7 h), no major changes in gene
expression level of VE-cadherin were detected with either
histamine or VEGF in our study. This indicates that clau-
din-5 may be more regulated at the transcriptional level,
whereas VE-cadherin is mainly regulated at the posttrans-
lational level [13]. Changes in claudin-5 expression have
been previously connected to pathological angiogenesis,
e.g., in cancer [30]. In addition to claudin-5, histamine
upregulated several cell adhesion molecules that is a
known hallmark of inflammation and H1R-mediated
signaling.
Decreased cell–cell adhesion has been reported to pro-
mote angiogenesis and is likely regulated by multiple
factors at the gene expression level. Also claudin-5 has
been connected to regulation of EC motility and matrix
adhesion [14, 15]. Previously, histamine has been sug-
gested to promote vessel growth in tumors, as well as to
induce EC proliferation and angiogenesis by upregulating
expression of VEGF or the pro-angiogenic transcription
factor NR4A1 [6, 31]. In our study, no upregulation of
VEGFs/VEGFRs was detected after histamine stimulation.
Additionally, inhibition experiments by VEGFR2 siRNA
did not reduce histamine-mediated regulation of specific
genes (e.g., RCAN1, CLDN5 and NR4A1). Therefore, our
results are in line with the previous finding of Qin et al. [6]
that histamine is able to induce VEGFR2-independent
angiogenic signaling. Moreover, we also show that the
cellular mechanisms required to induce angiogenic pro-
cesses by histamine are more complex than earlier reported
direct regulation via NR4A1 and instead involve changes
in the expression levels of multiple genes, including growth
factors, cytokines, transcription factors and calcium-de-
pendent cell signaling events. Altogether, 14 commonly
regulated genes were directly involved in cell proliferation
by histamine and VEGF. A common mediator of EC pro-
liferation was shown to be HGF, which has previously been
linked to induce EC proliferation via PI3K-Akt pathway
[20], and to be upregulated after ischemic injury [21] and
in cancer [20]. HGF, however, had no effect on claudin-5
expression in our study. To identify the transcription fac-
tors required for cell adhesion/proliferation by histamine
and VEGF, functional studies were further performed
based on RNA-seq data. SNAI2 was shown to be exclu-
sively regulated by VEGF, whereas NR4A1, MYCN and
RCAN1 were regulated by both factors. Of these factors
SNAI2, NR4A1 and MYCN were shown to act as upstream
regulators of CLDN5 and to be important factors in EC
migration. MYCN expression has been previously linked to
integrin-mediated cell adhesion and PI3K-mediated VEGF
regulation in neuroblastoma [26]. SNAI2 has been shown
to repress claudin-1 expression in keratinocytes [19] and to
be upregulated in pathological angiogenesis. RCAN1 has
been connected to VEGF signaling and regulation of
angiogenesis via NFAT signaling [32]. Importantly, prior
to this study, histamine signaling has not been connected to
these genes. Furthermore, we demonstrate that NR4A1,
MYCN and SNAI2 induce downregulation of claudin-5
and are required for EC migration. Since both NR4A1 and
RCAN1 have been shown to be upregulated after elevated
intracellular calcium levels [23, 33] and changes in gene
expression of calcium transporters were detected with both
histamine and VEGF, this together with HGF-induced
signaling may explain the observed similar gene expression
patterns found between the factors. We also demonstrate
that interleukin-8 regulates claudin-5 expression by his-
tamine via PI3K-independent pathway. This is in agree-
ment with a previous study, showing that interleukin-8
induces EC permeability and angiogenesis by downregu-
lating claudin-5 [22]. Overall, although the role of calcium
in mediating angiogenesis needs further clarification,
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calcium overload seems to lead to upregulation of multiple
TFs [34] that promote angiogenic processes in ECs by
histamine and VEGF. Besides our data, other TFs such as
FoxO1, Erg and Runx1 have been connected to regulate
claudin-5 after stimulation of ECs by Vegf, interleukin-1b
or thrombin [16–18, 35, 36]; however, changes in the
expression levels by these factors were not observed in our
study. This may indicate to cell-type-specific differences,
e.g., in aortic and venous ECs. These cell-type-specific
differences may also exist between histamine- and VEGF-
induced functional effects.
As VEGFs have been used to induce arteriogenesis and
angiogenesis to treat coronary and peripheral vascular
diseases, understanding their potential adverse effects is of
great importance for future clinical use. Our group previ-
ously demonstrated that VEGF therapy in preclinical ani-
mal models successfully induced blood vessel growth,
increased skeletal muscle perfusion but simultaneously
caused edema [37]. So far the mechanisms regulating cell–
cell adhesion and EC permeability have been poorly
understood, although numerous genes have been linked
with vascular permeability [38]. We show here that sys-
temic delivery of histamine and VEGF-F causes vascular
hyperpermeability of 200-nm-sized particles (\10 min) in
the intact vasculature of mice, whereas VEGF-A165 induces
a slower hyperpermeability response (\30 min). Previ-
ously, the majority of vascular permeability studies have
been performed locally in skin by using the modified Miles
assay. However, the Miles assay, although effective, has
been shown to induce inflammation at site or in individu-
ally perfused vessels [39]. Based on these methods, VEGF-
F has been suggested as a more potent vasodilator than
VEGF-A165 [40], whereas VEGF-A121 and VEGF-A165
induce similar local responses [11]. Our data, however,
show that VEGF-induced vascular hyperpermeability after
systemic delivery (1) varies among different vascular beds
and (2) is time dependent. Both VEGF-A165 and VEGF-F
cause similar responses over time. Time-dependent varia-
tion of VEGFs is likely explained by VEGF-A165 binding
to VEGFR1/VEGFR2, whereas VEGF-F only binds to
VEGFR2. To our knowledge, this is the first comprehen-
sive study evaluating VEGF-induced effects on vascular
permeability in intact vasculature of mice in various vas-
cular beds. Additionally, in our EC permeability model,
VEGF-A121 was not able to induce EC permeability or
induce changes in VE-cadherin localization or F-actin
organization. Additional differences were detected in the
expression levels of calcium-induced genes (e.g., ATP2B1,
SLC12A2, STC1) by VEGF-A121 and other VEGFR2-
binding VEGFs. The obtained knowledge is valuable for
safety evaluation of VEGFs for pro-angiogenic therapy.
Previously, EC function has been suggested to require
regulation not only at transient phosphorylation level but
also at transcriptional level [41]. In this study, we identified
novel common molecular players influencing EC activa-
tion, migration and adhesion by VEGFs and histamine. Our
results on the regulation of vascular endothelium improve
general understanding of pathological angiogenesis and
may provide novel treatment targets, such as RCAN1,
MYCN and SNAI2 for treatment of vascular pathologies.
Regulation of, e.g., MYCN signaling by CDK7 inhibitors
[42] or NR4A1 signaling by calcineurin inhibitors [43] may
also be beneficial in pro-angiogenic therapy to reduce
edema.
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